Defensive strategies of Bacillus anthracis that promote a fatal disease

Drug Discovery Today: Disease Mechanisms

Volumn 4, Issue 4, 2007, Pages 253-258

  Mogridge, Jeremy ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADENYLATE CYCLASE; ANTHRAX TOXIN; EDEMA TOXIN; LETHAL TOXIN; PROTEINASE; VIRULENCE FACTOR;

ANTHRAX; BACILLUS ANTHRACIS; BACTERIAL CELL WALL; BACTERIAL GROWTH; BACTERIAL IMMUNITY; BACTERIAL SPORE; BACTERIAL SURVIVAL; BACTERIAL TRANSLOCATION; BACTERIAL VIRULENCE; BLOOD VESSEL PERMEABILITY; EDEMA; HOST RESISTANCE; HUMAN; HYPOTENSION; IMMUNE RESPONSE; MULTIPLE ORGAN FAILURE; NONHUMAN; PATHOGENESIS; PHAGOCYTOSIS; REVIEW;

EID: 47049100870     PISSN: 17406765     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ddmec.2007.12.002     Document Type: Review

References (43)

1. Inglesby T.V., et al. Anthrax as a biological weapon, 2002: updated recommendations for management. JAMA 287 (2002) 2236-2252
2. Young J.A., and Collier R.J. Anthrax toxin: receptor binding, internalization, pore formation, and translocation. Annu. Rev. Biochem. 76 (2007) 243-265
3. Scobie H.M., and Young J.A. Interactions between anthrax toxin receptors and protective antigen. Curr. Opin. Microbiol. 8 (2005) 106-112
4. Santelli E., et al. Crystal structure of a complex between anthrax toxin and its host cell receptor. Nature 430 (2004) 905-908
5. Moayeri M., et al. Anthrax protective antigen cleavage and clearance from the blood of mice and rats. Infect. Immun. 75 (2007) 5175-5184
6. Lacy D.B., et al. A model of anthrax toxin lethal factor bound to protective antigen. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 16409-16414
7. Abrami L., et al. Receptor palmitoylation and ubiquitination regulate anthrax toxin endocytosis. J. Cell Biol. 172 (2006) 309-320
8. Wei W., et al. The LDL receptor-related protein LRP6 mediates internalization and lethality of anthrax toxin [see comment]. Cell 124 (2006) 1141-1154
9. Young J.J., et al. LRP5 and LRP6 are not required for protective antigen-mediated internalization or lethality of anthrax lethal toxin. PLoS Pathog. 3 (2007) e27
10. Abrami L., et al. Membrane insertion of anthrax protective antigen and cytoplasmic delivery of lethal factor occur at different stages of the endocytic pathway. J. Cell Biol. 166 (2004) 645-651
11. Rainey G.J., et al. Receptor-specific requirements for anthrax toxin delivery into cells. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 13278-13283
12. Dal Molin F., et al. Cell entry and cAMP imaging of anthrax edema toxin. EMBO J. 25 (2006) 5405-5413
13. Zhang S., et al. Evidence that translocation of anthrax toxin's lethal factor is initiated by entry of its N terminus into the protective antigen channel. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 16756-16761
14. Krantz B.A., et al. Protein translocation through the anthrax toxin transmembrane pore is driven by a proton gradient. J. Mol. Biol. 355 (2006) 968-979
15. Krantz B.A., et al. A phenylalanine clamp catalyzes protein translocation through the anthrax toxin pore. Science 309 (2005) 777-781
16. Ratts R., et al. A conserved motif in transmembrane helix 1 of diphtheria toxin mediates catalytic domain delivery to the cytosol. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 15635-15640
17. Shen Y., et al. Calcium-independent calmodulin binding and two-metal-ion catalytic mechanism of anthrax edema factor. EMBO J. 24 (2005) 929-941
18. Tessier J., et al. Contributions of histamine, prostanoids, and neurokinins to edema elicited by edema toxin from Bacillus anthracis. Infect. Immun. 75 (2007) 1895-1903
19. Firoved A.M., et al. Bacillus anthracis edema toxin causes extensive tissue lesions and rapid lethality in mice. Am. J. Pathol. 167 (2005) 1309-1320
20. Baldari C.T., et al. Anthrax toxins: a paradigm of bacterial immune suppression. Trends Immunol. 27 (2006) 434-440
21. Turk B.E., et al. The structural basis for substrate and inhibitor selectivity of the anthrax lethal factor. Nat. Struct. Mol. Biol. 11 (2004) 60-66
22. Alileche A., et al. Anthrax lethal toxin-mediated killing of human and murine dendritic cells impairs the adaptive immune response. PLoS Pathog. 1 (2005) e19
23. Boyden E.D., and Dietrich W.F. Nalp1b controls mouse macrophage susceptibility to anthrax lethal toxin. Nat. Genet. 38 (2006) 240-244
24. Ha S.D., et al. Mitochondrial proteins Bnip3 and Bnip3L are involved in anthrax lethal toxin-induced macrophage cell death. J. Biol. Chem. 282 (2007) 26275-26283
25. Banks D.J., et al. New insights into the functions of anthrax toxin. Expert Rev. Mol. Med. 8 (2006) 1-18
26. Moayeri M., et al. Bacillus anthracis lethal toxin induces TNF-alpha-independent hypoxia-mediated toxicity in mice. J. Clin. Invest. 112 (2003) 670-682
27. Watson L.E., et al. Anthrax toxins induce shock in rats by depressed cardiac ventricular function. PLoS ONE 2 (2007) e466
28. Candela T., and Fouet A. Poly-gamma-glutamate in bacteria. Mol. Microbiol. 60 (2006) 1091-1098
29. Joyce J., et al. Immunogenicity and protective efficacy of Bacillus anthracis poly-gamma-d-glutamic acid capsule covalently coupled to a protein carrier using a novel triazine-based conjugation strategy. J. Biol. Chem. 281 (2006) 4831-4843
30. Candela T., and Fouet A. Bacillus anthracis CapD, belonging to the gamma-glutamyltranspeptidase family, is required for the covalent anchoring of capsule to peptidoglycan. Mol. Microbiol. 57 (2005) 717-726
31. Drysdale M., et al. Capsule synthesis by Bacillus anthracis is required for dissemination in murine inhalation anthrax. EMBO J. 24 (2005) 221-227
32. Sellman B.R., et al. Dominant-negative mutants of a toxin subunit: an approach to therapy of anthrax. Science 292 (2001) 695-697
33. Maynard J.A., et al. Protection against anthrax toxin by recombinant antibody fragments correlates with antigen affinity. Nat. Biotechnol. 20 (2002) 597-601
34. Scobie H.M., et al. A soluble receptor decoy protects rats against anthrax lethal toxin challenge. J. Infect. Dis. 192 (2005) 1047-1051
35. Rai P., et al. Statistical pattern matching facilitates the design of polyvalent inhibitors of anthrax and cholera toxins. Nat. Biotechnol. 24 (2006) 582-586
36. Xiong Y., et al. The discovery of a potent and selective lethal factor inhibitor for adjunct therapy of anthrax infection. Bioorg. Med. Chem. Lett. 16 (2006) 964-968
37. Dell'Aica I., et al. Potent inhibitors of anthrax lethal factor from green tea. EMBO Rep. 5 (2004) 418-422
38. Shen Y., et al. Selective inhibition of anthrax edema factor by adefovir, a drug for chronic hepatitis B virus infection. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 3242-3247
39. Basha S., et al. Polyvalent inhibitors of anthrax toxin that target host receptors. Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 13509-13513
40. Sarac M.S., et al. Protection against anthrax toxemia by hexa-d-arginine in vitro and in vivo. Infect. Immun. 72 (2004) 602-605
41. Shiryaev S.A., et al. Targeting host cell furin proprotein convertases as a therapeutic strategy against bacterial toxins and viral pathogens. J. Biol. Chem. 282 (2007) 20847-20853
42. Scorpio A., et al. Poly-gamma-glutamate capsule-degrading enzyme treatment enhances phagocytosis and killing of encapsulated Bacillus anthracis. Antimicrob. Agents Chemother. 51 (2007) 215-222
43. Schuch R., et al. A bacteriolytic agent that detects and kills Bacillus anthracis. Nature 418 (2002) 884-889